Vitae May Look To Public Markets After Nearly A Decade Of Self-Sustained Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Alzheimer’s collaboration with Boehringer Ingelheim heads into the clinic, triggering a $14 million milestone payment to Vitae. But as the discovery specialist focuses more on autoimmune conditions and less on primary care, it also may want to increase involvement in clinical development and even commercialization of its discoveries.
You may also be interested in...
Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s
Two programs partnered with Germany’s Boehringer Ingelheim are advancing, with a type 2 diabetes program moving into Phase II while a beta secretase inhibitor for Alzheimer’s demonstrates strong ability to decrease amyloid beta levels in the brain. Vitae went public in September, netting $48.4 million from its IPO.
Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s
Two programs partnered with Germany’s Boehringer Ingelheim are advancing, with a type 2 diabetes program moving into Phase II while a BACE inhibitor for Alzheimer’s offers demonstrates strong ability to decrease amyloid beta levels in the brain. Vitae went public in September, netting $48.4 million from its IPO.
Autoimmune RORγt Program May Portend Change Of Direction For Vitae
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.